Results 151 to 160 of about 67,755 (267)

Mitochondrial transfer in acute myeloid leukaemia and multiple myeloma: Mechanisms, consequences and potential therapeutic opportunities

open access: yesThe FEBS Journal, EarlyView.
Mitochondria can be transferred from bone marrow cells to cancer cells in acute myeloid leukaemia and multiple myeloma, boosting tumour energy production, growth, and drug resistance. This review highlights key transfer mechanisms and shows how targeting mitochondrial movement and dynamics may offer new therapeutic strategies to limit cancer ...
Ebubechukwu Nwarunma   +1 more
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

open access: yesThe FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture   +3 more
wiley   +1 more source

Dual IRE1 targets: Determinants of the cell fate?

open access: yesThe FEBS Journal, EarlyView.
IRE1 is an ER stress sensor that restores protein homeostasis through two signaling activities: XBP1s, which upregulates its target gene expression or RIDD which downregulates its target transcripts. We recently identified Dual IRE1 Targets (DIT) which are modulated by both XBP1s and RIDD activities.
Eva Billat   +3 more
wiley   +1 more source

CD36‐mediated lipid rewiring in the metabolic adaptation of tumour ecosystems

open access: yesThe FEBS Journal, EarlyView.
Nutrient deprivation drives a lipid‐centric shift in tumour metabolic symbiosis and signalling network. CD36 functions as a bidirectional bridge, transferring fatty acids from stromal donors (adipocytes, CAFs) to the ecosystem tumour‐ and microenvironment‐dependently.
Anna Sebestyén   +11 more
wiley   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy